Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

GeneDx Holdings (WGS) Net Margin (2020 - 2025)

Historic Net Margin for GeneDx Holdings (WGS) over the last 6 years, with Q3 2025 value amounting to 6.54%.

  • GeneDx Holdings' Net Margin rose 42700.0% to 6.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.52%, marking a year-over-year increase of 317500.0%. This contributed to the annual value of 17.12% for FY2024, which is 696500.0% up from last year.
  • Per GeneDx Holdings' latest filing, its Net Margin stood at 6.54% for Q3 2025, which was up 42700.0% from 10.53% recorded in Q2 2025.
  • GeneDx Holdings' Net Margin's 5-year high stood at 75.8% during Q3 2021, with a 5-year trough of 503.2% in Q4 2022.
  • In the last 5 years, GeneDx Holdings' Net Margin had a median value of 44.89% in 2023 and averaged 88.67%.
  • As far as peak fluctuations go, GeneDx Holdings' Net Margin plummeted by -4336800bps in 2022, and later soared by 4583100bps in 2023.
  • Over the past 5 years, GeneDx Holdings' Net Margin (Quarter) stood at 69.52% in 2021, then plummeted by -624bps to 503.2% in 2022, then skyrocketed by 91bps to 44.89% in 2023, then surged by 113bps to 5.69% in 2024, then crashed by -215bps to 6.54% in 2025.
  • Its Net Margin stands at 6.54% for Q3 2025, versus 10.53% for Q2 2025 and 7.49% for Q1 2025.